Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Viking Thera (NQ: VKTX ) 68.85 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Viking Thera < Previous 1 2 3 4 5 6 7 8 9 ... 18 19 Next > Got $5,000? Viking Therapeutics Stock Just Got a Big New Green Flag November 07, 2024 The company's latest presentation supports the idea that its lead program will make billions. Via The Motley Fool Is Viking Therepautics a Buy Now? November 05, 2024 The clinical-stage drugmaker is developing an anti-obesity drug that could go on to produce record-breaking sales. Via The Motley Fool Why Viking Therapeutics Stock Plummeted After Soaring Today November 04, 2024 Are we ready for the Great Obesity Drug Gold Rush of the 2020s? Via The Motley Fool Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety November 04, 2024 Viking Therapeutics highlights VK2735's promising weight loss data at ObesityWeek 2024, with up to 14.7% reduction and improved prediabetic outcomes. Via Benzinga Viking Therapeutics Surges, Set To Break Out On Latest Obesity Drug Data November 03, 2024 The biotech reported strong weight loss for higher doses of its experimental obesity pill. Via Investor's Business Daily MarketBeat Week in Review – 10/28 - 11/1 November 02, 2024 Stocks staged a strong rally on Friday following a steep sell-off; a weak jobs report all but guarantees a rate cut which adds to bullish sentiment Via MarketBeat Topics Artificial Intelligence Economy Exposures Artificial Intelligence Interest Rates Unpacking the Latest Options Trading Trends in Viking Therapeutics October 29, 2024 Via Benzinga Here's How Much $100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today October 28, 2024 Via Benzinga Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH November 01, 2024 Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water. Via Investor's Business Daily Viking Therapeutics Stock: A Pre-Election Bet Worth Considering October 31, 2024 Viking Therapeutics is making headway in the weight loss drug market; but even though the payoff is years away, there's still plenty of upside for investors Via MarketBeat This High-Flying Stock Just Became a Better Buy October 31, 2024 It might not be too late to get in on the party. Via The Motley Fool Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution? October 27, 2024 Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star. Via The Motley Fool S&P 500, Nasdaq Rise Sharply Ending 3-Day Losing Streak; Viking Therapeutics Surge, While Capri’s Shares Slump October 25, 2024 US benchmark equity averages rose on Friday as the market ended a three-day losing streak. Via Talk Markets Topics Stocks Exposures US Equities 3 Health Care Stocks Moving In Thursday's Intraday Session October 24, 2024 Via Benzinga An Overview of Viking Therapeutics's Earnings October 22, 2024 Via Benzinga Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review October 25, 2024 The major indexes were mixed for the week. Via Investor's Business Daily Why Viking Therapeutics Stock Soared by Nearly 21% on Thursday October 24, 2024 The company provided clear evidence that it has plenty of resources to continue developing a potential blockbuster drug. Via The Motley Fool UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday October 24, 2024 Via Benzinga Market Whales and Their Recent Bets on VKTX Options October 22, 2024 Via Benzinga How Viking Therapeutics Just Dealt A Blow To Eli Lilly's Obesity Triplet October 24, 2024 Viking is planning to file with the FDA next year to begin testing a quadruple approach to weight loss. Via Investor's Business Daily Exposures Product Safety 3 Growth Stocks That Have Generated 1,000% Returns Since the Last Presidential Election (and They've All Outperformed Nvidia) October 24, 2024 Regardless of who wins the presidency, investors are better off focusing on top growth stocks. Via The Motley Fool Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition October 23, 2024 Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition. Via Benzinga Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains? October 22, 2024 Viking Therapeutics (VKTX) set to report Q3 earnings amid high expectations, thanks to promising weight-loss drug candidate. Stock up 240% YTD. Via Benzinga Viking Therapeutics Gives Investors Another Reason to Remain Bullish on Its Future October 17, 2024 Viking recently announced the results of an early-stage clinical trial for VK0214. Via The Motley Fool 10 Health Care Stocks With Whale Alerts In Today's Session October 16, 2024 Via Benzinga Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade October 14, 2024 The analyst is closely watching MariTide, a potential monthly injection to treat obesity. Via Investor's Business Daily Where Will Viking Therapeutics Be in 5 Years? October 14, 2024 We could be witnessing the birth of a major player in the biotech industry. Via The Motley Fool Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics October 13, 2024 It's hard to go wrong with either company, but one is more appealing. Via The Motley Fool The Ultimate Biotech Stock to Buy With $100 Right Now October 12, 2024 This company is operating in one of today's hottest markets. Via The Motley Fool Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names October 11, 2024 The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 18 19 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
